Subscribe 600$/product give away!
Submit an Article to Pharmacy HQ     
Please include the author's name, title, and citations.     

FROVA- frovatriptan succinate tablet, film coated

Patient Information

Advise the patient to read the FDA approved patient labeling (Patient Information).

Myocardial Ischemia and/or Infarction, Prinzmetal s Angina, Other Vasospastic Reactions, and Cerebrovascular Events

Inform patients that FROVA may cause serious cardiovascular adverse reactions such as myocardial infarction or stroke, which may result in hospitalization and even death. Although serious cardiovascular reactions can occur without warning symptoms, instruct patients to be alert for the signs and symptoms of chest pain, shortness of breath, weakness, slurring of speech, and instruct them to ask for medical advice when observing any indicative sign or symptoms. Instruct patients to seek medical advice if they have symptoms of other vasospastic reactions[see Warnings and Precautions (5.1,5.2,5.4,5.5, and5.8)].

Hypersensitivity Reactions

Inform patients that anaphylactic reactions have occurred in patients receiving FROVA. Inform patients that such reactions can be life threatening or fatal and to seek immediate medical attention if they have anaphylactic symptoms. In general, anaphylactic reactions to drugs are more likely to occur in individuals with a history of sensitivity to multiple allergens[see Contraindications (4)].

Medication Overuse Headache

Inform patients that use of drugs to treat acute migraines for 10 or more days per month may lead to an exacerbation of headache, and encourage patients to record headache frequency and drug use (e.g., by keeping a headache diary)[see Warnings and Precautions (5.6)].

Serotonin Syndrome

Inform patients about the risk of serotonin syndrome with the use of FROVA or other triptans, particularly during combined use with SSRIs, SNRIs, TCAs, and MAO inhibitors[see Warnings and Precautions (5.7) and Drug Interactions (7.3)].


Advise patients to notify their healthcare provider if they become pregnant during treatment or plan to become pregnant[see Use in Specific Populations (8.1)].


Inform patients to notify their healthcare provider if they are breastfeeding or plan to breastfeed[see Use in Specific Populations (8.2)].

Your use of this website constitutes your agreement to the terms and conditions linked below:
Terms and Conditions | Resources | Sitemap
2017 © Copyright Questions?
Please contact: